Vernalis up as Parkinson's drug passes safety trial
The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease.
The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease.
The double-blind, placebo-controlled study showed "a wide range of doses were found to be well tolerated with no unexpected safety findings."
The focus now shifts to a "receptor occupancy" study, scheduled to start in the second half of 2012.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
By 11:19 Vernalis shares had risen 1.4%.
BS
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Regulator moves to protect access to cash amid branch closures and disappearing ATMs
News The Financial Conduct Authority has told banks to start assessing if local communities have adequate cash access from mid-September
By Marc Shoffman Published
-
VAT hike on private school fees could come earlier than previously expected
The government could start charging VAT on private school fees as soon as January 2025, according to the latest reports. What does it mean for parents?
By Katie Williams Published